AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04319575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: root canal treatment and intracanal medicament
Description: after the access preparation and cleaning and shaping was done in 1st appointment using k files,Mani and protapers,Dentsply then in, chitosan calcium hydroxide paste, or ciprofloxacin metronidazole minocycline paste placed in the canal and kept for 4 weeks.
Study NCT04319575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: root canal treatment and intracanal medicament
Description: after the access preparation and cleaning and shaping was done in 1st appointment using k files,Mani and protapers,Dentsply then in, chitosan calcium hydroxide paste, or ciprofloxacin metronidazole minocycline paste placed in the canal and kept for 4 weeks.
Study NCT03045861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2838232
Description: GSK2838232 capsules will be supplied as swedish orange, unmarked capsule (50 mg), and white, unmarked capsules (10 mg) in high-density polyethylene bottles.
Study NCT03045861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Cobicistat tablets 150 mg will be supplied as an orange, round, biconvex, film-coated tablet in bulk containers for individualized dosing.
Study NCT02210065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)
Description: CTL product given as single infusion within 72 hours of CMV reactivation. CTL dose infused will be at a maximum dose of 10e5 viable CD3+ T cells/kg.
Study NCT04006132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitting of Ponto 3 SuperPower
Description: Bone-anchored hearing systems (BAHS) use the body's natural ability to transfer sound through bone conduction. The sound processor picks up sound and converts it into vibrations that are transferred through the skull bone to the inner ear (cochlea). Thus, for patients with conductive or mixed hearing losses, patients with lasting hearing loss following a middle ear disease or malformations (such as microtia), the vibrations are bypassing the conductive problem in the ear canal or middle ear. The intervention in this study is audiologically fitting two bone-anchored sound processors (Ponto 3 SuperPower) to patients that are already bilaterally implanted with abutments.
Study NCT02906748 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injection with a syringe in new-site for parathyroid autografting
Description: new-site for parathyroid autografting, close to the antecubital vein
Study NCT02349048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir 150 mg
Description: Simeprevir 150 mg capsule orally once daily.
Study NCT02349048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg
Description: Daclatasvir 60 mg tablet orally once daily.
Study NCT02349048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg
Description: Sofosbuvir 400 mg tablet orally once daily.
Study NCT03126942 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Novaloc
Description: Attachment composed by a polyetheretherketone (PEEK) capsule and carbon-coated abutment. The yellow (medium) retentive component will be used
Study NCT03126942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novaloc
Description: Attachment composed by a polyetheretherketone (PEEK) capsule and carbon-coated abutment. The yellow (medium) retentive component will be used
Study NCT03126942 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Locator
Description: Traditional cylindrical attachment (Locator system) with pink (medium) retentive components
Study NCT03126942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Locator
Description: Traditional cylindrical attachment (Locator system) with pink (medium) retentive components
Study NCT02203825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM-CS1 T-cell infusion
Description: Each patient will receive a single dose of CM-CS1 T-cells by intravenous infusion.
Study NCT05726799 — intervention group
Intervention type: PROCEDURE
Intervention: Cryo myectomy
Description: Extended septal myecotmy using cryo energy
Study NCT05726799 — intervention group
Intervention type: PROCEDURE
Intervention: Myectomy
Description: Classic surgical myectomy
Study NCT00806936 — intervention group
Intervention type: DRUG
Intervention: human insulin
Description: Any kind of human insulin administered at the discretion of the physician
Study NCT00806936 — intervention group
Intervention type: DRUG
Intervention: insulin analogue
Description: Any kind of insulin analogue administered at the discretion of the physician
Study NCT01322464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: 4 sprays Sativex in fasted state on Day 1. 4 sprays Sativex in fed state on Day 4. 4 sprays Sativex daily in fasted state Days 5-13.
Study NCT01322464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: 4 sprays Sativex in fed state on Day 1. 4 sprays Sativex in fasted state on Day 4. 4 sprays Sativex daily in fasted state Days 5-13.
Study NCT01322464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: 2 sprays Sativex daily in fasted state Days 4-13.
Study NCT01322464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: 8 sprays Sativex daily in fasted state Days 4-13.
Study NCT04697459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chronic phase
Description: 1h of intradialytic execise, starting 30 min after hemodialysis beginning : 30 min of low-intensity (Borg Scale 11-14) aerobic exercise + 30 min of resistance training, frequency : 3 times a week for 16 weeks.
Study NCT04697459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acute phase
Description: 30 min of low-intensity (Borg Scale 11-14) aerobic exercise, starting 30 min after hemodialysis beginning
Study NCT05288400 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg + bisoprolol fumarate 5mg + perindopril arginine 5mg
Description: 1 capsule/day Oral administration
Study NCT05288400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norvasc 5mg tablet
Description: Norvasc (amlodipine) 5mg, 1 tablet/day
Study NCT05288400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concor 5mg tablet
Description: Concor (bisoprolol fumarate) 5mg, 1 tablet/day
Study NCT05288400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coversyl 5mg tablet
Description: Coversyl (perindopril arginine) 5mg, 1 tablet/day
Study NCT03966742 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drug Eluting Bead Embolization (DEB) for Desmoid Fibromatosis
Description: Delivery of Doxorubicin selectively into Desmoid Fibromatosis utilizing its vascular supply as a conduit, and ionic loading the doxorubicin onto embolized particles as the drug delivery vehicle.~Maximal dose is 75 mg/m2 and at least 50 mg. The bead size is 75-300 Mµ in a 2 CC syringe.
Study NCT00003625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Study NCT00003625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00003625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00003625 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02835001 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchoscopy
Description: Two sequences of 30 minutes are necessary by patient
Study NCT02835001 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lung Volume Reduction Coil (HEAT-LVRC)
Description: Bronchoscopy with Heat-LVRC
Study NCT01236573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
Study NCT01236573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) over 1 hr.
Study NCT01236573 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-12 transduced TIL
Description: On day 0 (one to four days after the last dose of fludarabine), cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes.
Study NCT04164836 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: rhinoscope
Description: more suitable nose for nasotracheal intubation will be selected based on the view of rhinoscope.
Study NCT03568474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Description: Indirect pulp capping material
Study NCT03568474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glass Ionomer
Description: Indirect pulp capping material
Study NCT03568474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glass Ionomer
Description: Indirect pulp capping material
Study NCT03101228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced sitting
Description: Subjects are guided to limit their sitting time during the day for 1 hour/day, by adding light activity with the help of an activity monitor. Subjects are not encouraged to increase their moderate to vigorous physical activity levels.
Study NCT00597480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhGH (Norditropine SimpleXx®)
Description: the recommended dose in the EU of rhGH (Norditropine SimpleXx®
Study NCT00597480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhGH norditropine simple Xx
Description: the dose to achieve a treat-to target value of IGF-1 levels within a +1.5 to +2.5 SDS interval (starting dose, 0.067 mg/kg/day)
Study NCT03451786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL
Description: Intraocular lens
Study NCT04152577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R2-combination chemotherapy
Description: R2-CHOP/CHOPE/DA-EPOCH/HD MTX~R2-CHOP :~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R2-DA-EPOCH:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R2-HD MTX:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1
Study NCT04152577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-combination chemotherapy
Description: R-CHOP/CHOPE/DA-EPOCH/HD MTX~R-CHOP :~Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R-DA-EPOCH:~Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R-HD MTX:~Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1
Study NCT02159729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
Study NCT02159729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101 (1 mg/cm^2)
Description: Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
Study NCT02906748 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: injection with a syringe in traditional site for parathyroid autografting
Description: traditional-site for parathyroid autografting,not intensively close to the antecubital vein
Study NCT01046708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micronized progesterone
Description: 600mg in 3 separate doses per day
Study NCT03548948 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High heme iron diet
Description: A Typical American diet with high heme/non-heme iron (18 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet.
Study NCT03548948 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low iron diet
Description: A Typical American diet with low heme/non-heme iron (8 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet.
Study NCT02159729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101 (2 mg/cm^2)
Description: Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
Study NCT02159729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101 (4 mg/cm^2)
Description: Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
Study NCT01794572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan: 140 mg/m²is infused intravenously in 30 minutes on day -2 after IV anti-emetics (5-HT3 antagonists).
Study NCT01794572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem cell
Description: Autologous Peripheral Stem Cell Rescue : 2.5 10\^6 CD-34/Kg are re-infused in the central line on day 0 after adequate premedication.
Study NCT04777487 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: GCF obtaining
Description: 4 samples of gingival crevicular fluid, 1 from each quadrant of the patient's jaw, were collected by means of paper strips.
Study NCT00530114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 223
Description: 1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
Study NCT00530114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
Study NCT05288738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine 1 mcg/ml
Description: 34 patients received PCA morphine 1 mg/ml with combination of dexmedetomidine 1 mcg/ml
Study NCT05288738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine 2 mcg/ml
Description: 34 patients received PCA morphine 1 mg/ml with combination of dexmedetomidine 2 mcg/ml
Study NCT01920880 — intervention group
Intervention type: OTHER
Intervention: Quantitative Sensory Testing analysis
Study NCT00643266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recollection Training
Description: Participants are exposed to long lists of words. Each word is presented either visually or auditorily, and each word is repeated after a variable number of intervening words (the lag), in each the same modality, or the other modality. Participants are instructed to respond yes only to words repeated in the same modality. If a performance criterion is met, the lag is increased for the next session; if the performance criterion is not met, the same lag is repeated in the next session.
Study NCT00643266 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants view PowerPoint presentations on various topics related to memory and aging (e.g., structural brain changes, diet, stress, depression) and how each of these topics affect memory, and after each presentation, play a Jeopardy-like game to test their knowledge gain
Study NCT02448030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional electric stimulation
Description: The FES will be placed at the flexor muscles of the forearm and knee extensors, for evaluation of upper and lower limbs, respectively. The stimulation frequency will be 20 Hz. The pulse width used will be 0.5 milliseconds and the contraction time will be 60 seconds (TON: 60s) with a 1-second rest interval (TOFF: 1s). The total time of application will be determined for the muscle fatigue that will be evaluated by 10-point Borg scale and by the measurement of lactate accumulation that must not exceed 30 minutes. The intensity will be adjusted individually, taking into account the patient's ability to promote the full flexion of the wrist / knee extension and comfort during contractions. Along with the application of FES a 1 Kg overload will be applied to intensify the fatigue time.
Study NCT02448030 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isometric exercise
Description: For the upper limbs the isometric contraction exercise with handgrip will be performed for 5 minutes with 30% of loading, previously measured by maximum voluntary contraction test. For the lower limbs the knee extension exercise will be conducted in a training station. The SBP, DBP, MBP and HR will be recorded through the protocols. Fatigue will be determined every minute by the 10-point Borg scale and by measurement of lactate accumulation before, immediately after the protocol, and 5 minutes during the recovery period.
Study NCT03695575 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Bone-conduction headset
Description: A bone-conduction headset paired with a microphone will be used.
Study NCT03744351 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biological Samples
Description: Venous sampling that is performed solely for the purpose of research. The total blood volume taken is 80 ml maximum (8 tubes of 10 ml).
Study NCT03744351 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biological Samples
Description: Eight additional 10 ml tubes of blood and an additional 5 ml CSF tube will be taken from the patient during a sample taken for the patient's usual check-up /follow-up.~Inpatients will also be offered stool removal.
Study NCT03744351 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biological Samples
Description: The patient will be taken 8 additional tubes of 10 ml of blood (during a blood test performed for the usual assessment of the patient) and an additional 5 ml of CSF in a sample taken for the assessment of the patient.
Study NCT03744351 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biological Samples
Description: Eight additional 10 ml tubes of blood will be taken from the patient during a sample taken for the patient's usual check-up / follow-up.~Inpatients will also be offered stool removal
Study NCT04565964 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: change the health behaviors to clean indoor environment
Description: Sheets and all covers should be wash weekly. Clean indoor environment with a vacuum cleaner twice a week
Study NCT00393887 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodesign IHM
Description: Biodesign IHM is placed to reinforce the hernia repair
Study NCT00393887 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polypropylene mesh
Description: Polypropylene mesh is used to reinforce the hernia repair.
Study NCT02152085 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narrow pulse
Description: Participants will be randomly assigned to one of two study arms to receive a 6 week treatment of electrical stimulation that comprises narrow (0.4 ms) stimulus pulses.
Study NCT02152085 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wide pulse
Description: Participants will be randomly assigned to one of two study arms to receive a 6 week treatment of electrical stimulation that comprises wide (1 ms) stimulus pulses.
Study NCT02214966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan/Ramipril, fixed dose combination tablet
Study NCT02214966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Ramipril, fixed dose combination tablet
Study NCT02214966 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high fat, high caloric meal
Study NCT02953340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-2012
Description: Supplied in prefilled single-use syringes for subcutaneous injection, administered on Day 2 of each cycle
Study NCT02953340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Subcutaneous injection administered on Day 2 of each cycle.
Study NCT02953340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m\^2 IV infusion administered on Day 1 of each cycle
Study NCT02953340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600mg/m\^2 IV infusion administered on Day 1 of each cycle
Study NCT04623684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microdrop administration [phenylephrine 1.67% + tropicamide 0.33% (drop volume: 6-7 μL)]
Description: 1 drop (6-7 μL) for 3 doses, 5 minutes' intervals
Study NCT04623684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard drop administration [phenylephrine 1.67% + tropicamide 0.33% (drop volume: 28-34 μL)]
Description: 1 drop (28-34 μL) for 3 doses, 5 minutes' intervals
Study NCT03234387 — intervention group
Intervention type: OTHER
Intervention: No intervention - only assessments.
Description: No intervention only a number of assessments. Participants will be assessed during a maximal cardiopulmonary exercise testing on an exercise bike during 1 visit, and before and after an oral glucose tolerance test on a following visit.
Study NCT04026724 — intervention group
Intervention type: DRUG
Intervention: Chinese patent medicine
Description: Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill.
Study NCT03945526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Astaxanthine